4.7 Article

Validation of the Lymph Node Ratio as a Prognostic Factor in Patients With N1 Nonsmall Cell Lung Cancer

Journal

CANCER
Volume 117, Issue 20, Pages 4724-4731

Publisher

WILEY
DOI: 10.1002/cncr.26093

Keywords

nonsmall cell lung cancer; lymph node metastasis; lymph node ratio; nonsmall cell lung cancer staging; Surveillance; Epidemiology, and End Results database

Categories

Funding

  1. Doris Duke Foundation for Clinical Research
  2. National Cancer Institute [5R01CA131348-03]
  3. Glaxo-Smith-Kline

Ask authors/readers for more resources

BACKGROUND: The number of positive lymph nodes (LNs) has been proposed as a prognostic indicator in N1 nonsmall cell lung cancer (NSCLC). However, the number of positive LNs is confounded by the number of LNs resected during surgery. The lymph node ratio (LNR) (the ratio of the number of positive LNs divided by the number of LNs resected) can circumvent this limitation. The prognostic significance of the LNR has been demonstrated in elderly patients with NSCLC. The objective of the current study was to evaluate whether a higher LNR is a marker of worse survival in patients with NSCLC aged <= 65 years who have N1 disease. METHODS: The Surveillance, Epidemiology, and End Results database was used to identify 4004 patients who underwent resection for N1 NSCLC. Patients were classified into 3 groups according to LNR (<= 0.15, 0.16-0.5, and >0.5). Associations of the LNR with lung cancer-specific and overall mortality were evaluated using the Kaplan-Meier method. Stratified and Cox regression analyses were used to assess correlations between the LNR and survival after adjusting for other prognostic factors. RESULTS: Unadjusted analysis indicated that a higher LNR was associated with worse lung cancer-specific survival (P < .0001) and overall survival (P < .0001). Stratified and multivariate analyses also indicated that the LNR was an independent predictor of survival after controlling for potential confounders. CONCLUSIONS: The current results confirmed that the LNR is an independent prognostic factor for survival in patients with N1 NSCLC. This information may be used to identify patients who are at greater risk of cancer recurrence. Cancer 2011;117:4724-31. (C) 2011 American Cancer Society.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available